Augmentin Liquid Dosing for Adults

Standard Liquid Dosing Regimens

The American College of Physicians recommends 500 mg amoxicillin/125 mg clavulanate three times daily for mild-to-moderate infections, including skin/soft tissue infections, uncomplicated urinary tract infections, and mild respiratory infections 1, 2
For respiratory tract infections, the Infectious Diseases Society of America recommends 875 mg/125 mg twice daily, which is preferred for acute bacterial rhinosinusitis, community-acquired pneumonia, and acute exacerbations of chronic bronchitis 1, 2

The Infectious Diseases Society of America guidelines recommend using 2000 mg amoxicillin/125 mg clavulanate twice daily when treating infections in patients at risk for drug-resistant Streptococcus pneumoniae, such as those with recent antibiotic use, immunodeficiency, or frequent daycare exposure 3, 4
The American Academy of Otolaryngology-Head and Neck Surgery recommends this high-dose regimen for adults with moderate disease or recent antibiotic exposure within 4-6 weeks 5

The standard dosing regimen should not be substituted with two 250 mg doses for one 500 mg dose, as this results in excessive clavulanate dosing and increased gastrointestinal side effects 1
For patients with severe renal impairment (GFR <30 mL/min), the dose should be reduced, with 250-500 mg every 12 hours for GFR 10-30 mL/min and 250-500 mg every 24 hours for GFR <10 mL/min 1

If no clinical improvement occurs after 72 hours, the American Academy of Otolaryngology-Head and Neck Surgery recommends switching to a respiratory fluoroquinolone (levofloxacin, moxifloxacin) or considering alternative diagnoses 5, 2
The patient should be reevaluated for complications or non-bacterial etiology 5

Liquid formulations should not be used interchangeably with tablets without calculating equivalent amoxicillin doses, as the clavulanate ratios differ between formulations 1
The full course of treatment should be completed even if symptoms improve early to prevent treatment failure and resistance development 1